RSV – Global Health Press

GHP News Latest Science

Literature update ViVa week 35-2026

1. GBS vaccine candidate clears a first key hurdle in HIV-endemic Africa A Ugandan phase 2 trial shows a hexavalent GBS6 vaccine candidate is safe and equally immunogenic in pregnant women with and without HIV, offering...

3 September, 2026

8 min read

Latest Science

Literature update ViVa week 32-2026

1. When strep throat explains MS – vaccination to prevent EBV-complications? Summary: This Viewpoint proposes that Epstein-Barr virus (EBV) drives multiple sclerosis (MS) through a mechanism analogous to group A...

12 August, 2026

8 min read

GHP News Latest Science

Literature update

1. RSV maternal vaccine vs infant immunization (Netherlands) Dutch researchers explored how pregnant women view the two new RSV prevention options for infants: a maternal RSV vaccine in pregnancy and an infant...

8 April, 2026

20 min read

GHP News Latest Science

Vaccines and Vaccination (ViVa) – today and tomorrow looking at WHO’s Immunization Agenda 2030 (IA2030)

The trajectory of vaccine development in high‑income countries is approaching a turning point. With the licensure of respiratory syncytial virus (RSV) vaccines and monoclonal antibodies, most high‑incidence, high‑burden...

9 March, 2026

8 min read

GHP News Infographic

Key Characteristics of Licensed RSV Immunization Products

Download Infographic Overview This infographic is designed to help readers think critically about whether vaccination against specific vaccine-preventable diseases is appropriate for them. It encourages individuals to...

18 February, 2026

1 min read

GHP News Latest Science

RSV and RSV vaccination – summary for clinicians

Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA pneumovirus with 2 key surface glycoproteins, the fusion (F) protein and the attachment (G) protein, which are the principal targets...

18 February, 2026

8 min read

GHP News Latest Science

Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada

Critical Summary This article evaluates the cost-effectiveness of recently available respiratory syncytial virus (RSV) immunization options—nirsevimab (a long-acting monoclonal antibody) and the maternal RSVpreF...

4 December, 2025

4 min read

GHP News Latest Science

Updated evidence for COVID-19, RSV, and Influenza vaccines for 2025–2026

SummaryThis comprehensive systematic review by leading US researchers, published in the New England Journal of Medicine, synthesizes new evidence on the effectiveness and safety of COVID-19, RSV, and influenza vaccines...

4 November, 2025

3 min read

GHP News Latest Science

CLEVER Trial – Clesrovimab for prevention of RSV disease in healthy infants

Reference: Zar HJ, Simões EAF, Madhi SA, et al. Clesrovimab for prevention of RSV disease in healthy infants. N Engl J Med. 2025;393(13):1292-1303. Background and Study Rationale Clesrovimab is engineered as a long...

7 October, 2025

7 min read

GHP News Latest Science

RSV prefusion F vaccine for prevention of hospitalization in older adults

The DAN-RSV phase 4 pragmatic randomized trial evaluated the effectiveness and safety of the bivalent RSV prefusion F protein–based vaccine (RSVpreF) in adults aged 60 years and older during the 2024–2025 season in...

9 September, 2025

2 min read

Tag - RSV